These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38055239)

  • 1. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
    Al-Janabi A; Alabas OA; Yiu ZZN; Foulkes AC; Eyre S; Khan AR; Reynolds NJ; Smith CH; Griffiths CEM; Warren RB;
    JAMA Dermatol; 2024 Jan; 160(1):71-79. PubMed ID: 38055239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
    Pina Vegas L; Penso L; Claudepierre P; Sbidian E
    JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
    Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
    Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
    Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
    Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.
    Singla S; Putman M; Liew J; Gordon K
    Lancet Rheumatol; 2023 Apr; 5(4):e200-e207. PubMed ID: 38251522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics.
    Al-Janabi A; Eyre S; Foulkes AC; Khan AR; Dand N; Burova E; DeSilva B; Makrygeorgou A; Davies E; Smith CH; Griffiths CEM; Morris AP; Warren RB;
    J Invest Dermatol; 2023 Aug; 143(8):1470-1478.e1. PubMed ID: 36804406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis.
    Penso L; Dray-Spira R; Weill A; Pina Vegas L; Zureik M; Sbidian E
    JAMA Dermatol; 2021 Sep; 157(9):1056-1065. PubMed ID: 34287624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis.
    Balakirski G; Burmann SN; Hofmann SC; Kreuter A
    J Dermatolog Treat; 2023 Dec; 34(1):2258240. PubMed ID: 37705378
    [No Abstract]   [Full Text] [Related]  

  • 9. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.
    Al-Janabi A; Foulkes AC; Mason K; Smith CH; Griffiths CEM; Warren RB
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1440-1448. PubMed ID: 31997406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data.
    Ding L; Chen C; Yang Y; Zhang X
    Front Immunol; 2024; 15():1349636. PubMed ID: 38384460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics.
    Al-Janabi A; Martin P; Khan AR; Foulkes AC; Smith CH; Griffiths CEM; Morris AP; Eyre S; Warren RB;
    J Allergy Clin Immunol; 2023 Nov; 152(5):1237-1246. PubMed ID: 37536512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Dand N; Barker JN; Smith CH; Griffiths CEM;
    Br J Dermatol; 2024 Apr; 190(5):689-700. PubMed ID: 38051972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.
    Tsiogka A; Liakou AI; Agiasofitou E; Gregoriou S; Stratigos A; Rigopoulos D; Kontochristopoulos G
    Dermatology; 2023; 239(6):937-941. PubMed ID: 37579735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Yiu ZZN; Ashcroft DM; Evans I; McElhone K; Lunt M; Smith CH; Walton S; Murphy R; Reynolds NJ; Ormerod AD; Griffiths CEM; Warren RB;
    Br J Dermatol; 2019 Feb; 180(2):329-337. PubMed ID: 30070708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical reactions and biologic agents: a French cohort study of 9303 patients.
    Bataille P; Layese R; Claudepierre P; Paris N; Dubiel J; Amiot A; Sbidian E;
    Br J Dermatol; 2022 Nov; 187(5):676-683. PubMed ID: 35770735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Yiu ZZN; Smith CH; Ashcroft DM; Lunt M; Walton S; Murphy R; Reynolds NJ; Ormerod AD; Griffiths CEM; Warren RB;
    J Invest Dermatol; 2018 Mar; 138(3):534-541. PubMed ID: 29054603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eczematous reactions in patients with plaque psoriasis receiving biological therapy: an observational study.
    Burlando M; Megna M; Caldarola G; Bernardini N; Giofré C; Gisondi P; De Simone C; Cozzani E
    Eur Rev Med Pharmacol Sci; 2024 Sep; 28(18):4298-4301. PubMed ID: 39359201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
    Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
    JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Lunt M; Smith CH; Griffiths CEM;
    Br J Dermatol; 2023 Aug; 189(3):271-278. PubMed ID: 37226927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.